P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES

Bibliographic Details
Main Authors:	Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, David Huggar, Angelica Falkenstein, Adeola Y. Makinde, Emily Bland, Jalyna Laney, Marné Garretson, Ali Mcbride
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969836.64813.8a

Similar Items

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
by: Sudipto Mukherjee, et al.
Published: (2024-01-01)

P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
by: Keri Maher, et al.
Published: (2023-08-01)

Luspatercept in patients with lower-risk myelodysplastic syndromes
by: Fenaux, P, et al.
Published: (2020)

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
by: D Valcárcel, et al.
Published: (2024-10-01)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024-03-01)

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA
by: Y. Gong, et al.
Published: (2024-01-01)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
by: S. Mukherjee, et al.
Published: (2022-06-01)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
by: Sigurd Delanghe, et al.
Published: (2022-12-01)

P733: DHX9 HELICASE DYSFUNCTION CONTRIBUTES TO DISEASE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: N.-F. Huang, et al.
Published: (2022-06-01)

Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives
by: Bert Heyrman, et al.
Published: (2024-10-01)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
by: Shamis Khan, et al.
Published: (2022-08-01)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
by: Eleftheria Hatzimichael, et al.
Published: (2022-10-01)

Highlights on the Luspatercept Treatment in Thalassemia
by: Yesim Aydinok
Published: (2023-02-01)

LUSPATERCEPT – A TREATMENT FOR THALASSEMIA?
by: Taimoor Hassan
Published: (2021-09-01)

LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
by: M Díez-Campelo, et al.
Published: (2024-10-01)

LONG-TERM EFFECTIVENESS AND SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: DVS Cavalcante, et al.
Published: (2024-10-01)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
by: Srinivas Aluri, et al.
Published: (2023-08-01)

P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL
by: P. Fenaux, et al.
Published: (2022-06-01)

FIRST SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
by: A. Jonasova, et al.
Published: (2024-01-01)

EFFICACY AND SAFETY OF LUSPATERCEPT IN MYELODYSPLASTIC SYNDROME/NEOPLASM WITH VERY LOW/LOW/INTERMEDIATE RISK REQUIRED TRANSFUSION: A SYSTEMATIC REVIEW AND SINGLEARM META-ANALYSIS
by: VC Monici, et al.
Published: (2024-10-01)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
by: Nicholas Jackson, et al.
Published: (2020-07-01)

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa
by: Anna Jonasova, et al.
Published: (2024-10-01)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
by: Julio Delgado, et al.
Published: (2021-08-01)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
by: Xiangke Xin, et al.
Published: (2025-02-01)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
by: Khaled M. Musallam, et al.
Published: (2023-08-01)

Effect of leaf position and days post-infiltration on transient expression of colorectal cancer vaccine candidate proteins GA733-Fc and GA733-FcK in Nicotiana benthamiana plant
by: Kibum Kim, et al.
Published: (2021-04-01)

Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation
by: Howard Oster, et al.
Published: (2023-06-01)

Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study
by: Chunkang Chang, et al.
Published: (2025-02-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

USO DE LUSPATERCEPTE EM NEOPLASIA MIELODISPLÁSICA COM SIDEROBLASTOS EM ANEL
by: MSP Pedrosa, et al.
Published: (2023-10-01)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
by: Antonio Piga, et al.
Published: (2022-12-01)

تجليات الفرح و الحزن في شعر ابن زمرك الأندلســـي (733-797 هـــ)
by: عبد الحافظ السبعاوي
Published: (2024-06-01)

Ante Orlović Gospodarski kriminalitet u Republici Hrvatskoj Redak, Split, 2013., str. 733
by: Lucija Sokanović
Published: (2014-02-01)

Histopathological Distribution of Thyroid Tumors in and around the Van Province, Turkey: Retrospective Analysis of 733 Cases
by: Remzi Erten, et al.
Published: (2019-07-01)

Ante Orlović Gospodarski kriminalitet u Republici Hrvatskoj Redak, Split, 2013., str. 733
by: Lucija Sokanović
Published: (2014-01-01)

Democratic Constitutionalism and Strategic Litigation: The Brazilian Writ of Injuntion N. º 4.733 Case
by: Renata de Marins Jaber Maneiro, et al.
Published: (2016-12-01)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
by: Ali T. Taher, et al.
Published: (2023-08-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01)

Luspatercept in β‐thalassemia: Who and when. Strengths and weaknesses points of a real‐world evidence
by: Lorenza Torti, et al.
Published: (2024-12-01)